Immune-Related Polyneuropathy and Generalized Myoclonus Associated with Pembrolizumab in a Patient with Metastatic Melanoma: A Case Report and Literature Review
Pembrolizumab is used to treat metastatic melanoma but may cause neurological immune-related adverse events involving the peripheral and central nervous systems. We report a 45-year-old man who developed painful sensory-motor polyneuropathy and clinically identified negative myoclonus during pembrolizumab-based treatment. Initial cerebrospinal fluid analysis showed lymphocytic pleocytosis and elevated protein, followed by albuminocytologic dissociation on repeat sampling. Electroencephalography (EEG) was unavailable. The initial episode was classified clinically as grade 2 and improved after corticosteroids and symptomatic treatment. Following pembrolizumab reintroduction, severe neurological symptoms recurred in September 2024, with a modified Rankin Scale score of 4, leading to permanent discontinuation. An August 2025 electrophysiological report described persistent severe mixed axonal and demyelinating sensory-motor neuropathy. The patient subsequently developed systemic and brain metastatic progression and died in April 2026. The temporal course supports suspected treatment-related neurological toxicity, but incomplete etiological and electrophysiological characterization limits causal attribution, particularly for myoclonus.
Authors
- Caio Augusto Pereira (ORCID: https://orcid.org/0009-0004-8601-9964)
- Jorge Alberto Martins Pentiado (ORCID: https://orcid.org/0009-0008-3614-4846)
- Jonatas Crispim Magalhães de Oliveira
- Lucas Ravagnani Silva
- Thales Pardini Fagundes (ORCID: https://orcid.org/0000-0002-3302-9913)
- Sérgio Vicente Serrano
- Caio Semensato Borges
Institutions
- Hospital de Câncer de Barretos (BR)
Publication Details
- Journal
- Brazilian Journal of Case Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.52600/2763-583x.bjcr.2026.6.1.bjcr237
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00